Anturec Pharmaceuticals

Anturec Pharmaceuticals is a private, preclinical-to-clinical stage biotech developing a novel vascular-targeted cancer therapy. The company's platform centers on tTF-NGR, a fusion protein designed to selectively occlude tumor blood vessels, leading to tumor death. With its lead program now in a pivotal Phase III trial for soft tissue sarcoma, Anturec is advancing a potentially broad-acting oncology therapeutic. The company is led by its founding scientists and a private investor, with operations split between Frankfurt and Münster, Germany.

Platform based on a human tissue factor (tTF) fusion protein. The protein is engineered to target CD13 on tumor vascular cells, inducing localized coagulation, vascular occlusion, and tumor infarction.

Competition includes other vascular-disrupting agents and targeted therapies in sarcoma. The primary competitive advantage is the novel, tumor-vasculature-specific mechanism of action (targeted occlusion vs. anti-angiogenesis). Success will depend on demonstrating superior efficacy/safety versus standard care and other combinations.